EUVIMEDEUVIMED entdecken
Open Access

Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study

Carlo Lombardi, Alvise Berti, Francesco Menzella, Marcello Cottini

Drugs in Context · 26.08.2025 · 14 · 1-9

DOI: 10.7573/dic.2025-6-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 26.08.2025. Verfasst von Carlo Lombardi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departmental Unit of Allergology & Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cough is a major symptom of asthma and is associated with poor clinical outcomes. However, current guidelines place little emphasis on the crucial relevance of the cough symptom and its treatment. The objective of this study was to assess the impact of dupilumab on chronic cough (CC) in patients with severe eosinophilic asthma (SEA) and chronic rhinosinusitis with nasal polyps (CRSwNP).

Methods

Patients with CC and SEA, CRSwNP, or SEA plus CRSwNP treated with dupilumab were prospectively included. Patients were evaluated before and after 6 months of treatment by collecting Severe Cough Visual Analogue Scale (SC-VAS) scores and the Leicester Cough Questionnaire (LCQ). A total of 67 patients with CC were included.

Results

Both SC-VAS and LCQ significantly improved after 6 months in the whole group (paired t-test SC-VAS, mean (SD), from 83.13 (11.54) to 38.21; and LCQ, from 1.98 (0.78) to 4.54 (1.35), both p

Schlagwörter

Stichwörter der Autor:innen

chronic coughchronic rhinosinusitis with nasal polypsdupilumab and quality of lifesevere eosinophilic asthmaunified airway disease

Autor:innen und Institutionen

  • Departmental Unit of Allergology & Pneumology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.
  • Center for Medical Sciences (CISMed) and Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
  • Santa Chiara Regional Hospital, APSS, Trento, Italy.
  • Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), Azienda ULSS2 Marca Trevigiana, Italy.
  • Allergy and Pneumology Outpatient Clinic, Bergamo, Italy.

Zitieren

APA

Lombardi, C., Berti, A., Menzella, F., & Cottini, M. (2025). Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study. Drugs in Context, 14, 1-9. https://doi.org/10.7573/dic.2025-6-3

Vancouver

Lombardi C, Berti A, Menzella F, Cottini M. Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study. Drugs in Context. 2025;14:1-9. doi:10.7573/dic.2025-6-3

BibTeX
@article{Lombardi2025,
  author = {Lombardi, Carlo and Berti, Alvise and Menzella, Francesco and Cottini, Marcello},
  title = {Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study},
  journal = {Drugs in Context},
  year = {2025},
  volume = {14},
  pages = {1--9},
  doi = {10.7573/dic.2025-6-3}
}
Kostenlos starten →